Diversity Oriented Approach to Triazole Based Peptidiomimetics by Click Chemistry as Mammalian Sterile 20 Kinase Inhibitors

S.Kotha^{1*}, D.Goyal¹, A.Bitra¹, N.Thota¹, G.Kruger², R.Anand^{1*}

- 1. Department of Chemistry, IIT Bombay, Powai, Mumbai, India.
- 2. Department of Chemistry, University of KwaZulu-Natal, Durban, South Africa.

Supporting Information

Table of Contents

- 1. General Experimental
- 2. Prepration of Compounds 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- 3. Table S1
- 4. Figure S1
- 4. ¹H NMR and ¹³C NMR spectra of compound 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20

General Experimental:

All the reactions were monitored by employing TLC technique using appropriate solvent system for development. Reactions involving air/oxygen sensitive reagents or catalysts were performed in degassed solvents. Transfer of moisture sensitive materials were carried out in a glove box, using standard syringe-septum techniques and the reactions were maintained under nitrogen atmosphere until the work up. Yields reported are isolated yields of the materials. All the commercial reagents were used as such without further purification. Infrared (IR) spectra were recorded on Nicolet Impact-400 FT IR spectrometer in KBr. Proton Nuclear Magnetic Resonance (400 MHz, ¹H NMR) spectra and Carbon Nuclear Magnetic Resonance (100 MHz, ¹³C NMR) spectra were recorded on Bruker/ Varian spectrometers. The high-resolution mass measurements were carried out using Micromass Q-Tof spectrometer. Melting points were recorded on Buchi B-545.

Preparation of compound (2)

According to the general procedure, alkyne **1a** (50 mg, 0.16 mmol), phenylazide (18.2 mg, 0.16 mmol), Cu(OAc)₂ (3.2 mg, 0.02 mmol) and sodium ascorbate (6.26 mg, 0.03 mmol) in ¹BuOH/H₂O (3:3 mL) was stirred at rt for 23 h. The crude mixture was purified by column

chromatography (100% ethyl acetate) to give the desired compound 2 (66 mg, 97%) as a white solid.

 \mathbf{R}_f : 0.20 (80% ethyl acetate/ petroleum ether).

Mp:176-178 °C.

¹H NMR (400 MHz, CDCl₃): δ = 2.01 (s, 3H), 3.01-3.29 (m, 3H), 3.31-3.60 (m, 1H), 3.63 (s, 3H), 4.73-4.86 (m, 2H), 7.02 (d, J = 7.5 Hz, 1H), 7.06-7.10 (m, 2H), 7.16 (d, J = 8.1 Hz, 1H), 7.18-7.29 (m, 3H), 7.41-7.43 (m, 1H), 7.55-7.64 (m, 2H), 7.67-7.70 (m, 2H), 7.77 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 23.4, 27.5, 37.8, 52.4, 52.8, 53.3, 120.6, 121.1, 127.3, 128.7, 128.9, 129.4, 129.9, 135.9, 137.1, 144.2, 170.6, 170.9, 171.7 ppm.

I.R. (KBr): 1542.4, 1648.2, 1735.4, 2926.5, 3306.2 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{23}H_{26}N_5O_4$ [M+H]⁺ 436.1985, found: 436.1976. [α]_D²⁵: - 10.0 (c = 0.15, CHCl₃).

Preparation of compound (3)

According to the general procedure, alkyne **1a** (20 mg, 0.06 mmol), *o*-nitrophenylazide (9.8 mg, 0.06 mmol), Cu(OAc)₂ (1.2 mg, 0.006 mmol) and sodium ascorbate (2.4 mg, 0.01 mmol) in ^tBuOH/H₂O (3:3 mL) was stirred at rt for 20 h. The crude mixture was purified by column chromatography (50% ethyl acetate/ petroleum ether) to give the compound **3** (25.2 mg, 82%) as a white solid.

 \mathbf{R}_{f} : 0.65 (80% ethyl acetate/ petroleum ether).

Mp: 197-199 °C.

¹**H NMR (400 MHz, CDCl₃):** δ = 2.02 (s, 3H), 3.02-3.15 (m, 3H), 3.32-3.37 (m, 1H), 3.67 (s, 3H), 4.74-4.79 (m, 1H), 4.81-4.85 (m, 1H), 6.81 (d, J = 7.6 Hz, 1H), 6.92 (d, J = 7.8 Hz, 1H), 7.09-7.19 (m, 2H), 7.20-7.28 (m, 3H), 7.62-7.64 (m, 2H), 7.67 (s, 1H), 7.70-7.81 (m, 1H), 8.07-8.09 (m, 1H) ppm.

¹³C NMR (100 MHz, CDCl₃+CD₃OD): $\delta = 22.5, 27.7, 37.5, 52.4, 53.5, 124.3, 125.5, 127.1, 127.9, 128.7, 129.2, 130.0, 130.9, 133.9, 136.0, 143.6, 144.4, 170.7, 171.5, 171.9 ppm.$

I.R. (KBr): 1263.7, 1656.7, 1736.5, 2930.0, 3291.8 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{23}H_{25}N_6O_6 [M+H]^+ 481.1836$, found: 481.1830. $[\alpha]_D^{25}$: -9.900 (c = 0.12, CH₃OH).

Preparation of compound (4)

According to the general procedure, alkyne **1a'** (20.0 mg, 0.06 mmol), *o*-nitrophenylazide (9.8 mg, 0.06 mmol), Cu(OAc)₂ (1.2 mg, 0.006 mmol) and sodium ascorbate (2.4 mg, 0.01 mmol) in ^tBuOH/H₂O (3:3 mL) was stirred at rt for 20 h. The crude mixture was purified by column chromatography (50% ethyl acetate/ petroleum ether) to give the compound **4** (27.1 mg, 88%) as a white solid.

 \mathbf{R}_f : 0.50 (60% ethyl acetate/ petroleum ether).

Mp: 175-177 °C.

¹**H NMR (400 MHz, CD₃OD):** δ = 1.93 (s, 3H), 2.99-3.27 (m, 4H), 3.65 (s, 3H), 4.65-4.69 (m, 1H), 4.74-4.78 (m, 1H), 7.18-7.19 (m, 3H), 7.20-7.28 (m, 2H), 7.75-7.80 (m, 2H), 7.82-7.91 (m, 1H), 8.09 (s, 1H), 8.13-8.15 (m, 1H) ppm.

¹³C NMR (100 MHz, CD₃OD): δ = 22.6, 28.9, 38.4, 52.8, 54.0, 55.4, 125.9, 126.7, 128.0, 128.9, 129.6, 130.4, 131.3, 132.4, 135.3, 138.0, 145.2, 146.1, 172.8, 173.3, 173.3 ppm.

I.R. (KBr): 1449.5, 1663.3, 1742.6, 2942.2, 3403.8 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{23}H_{25}N_6O_6$ [M+H]⁺ 481.1836, found: 481.1826. [α]_D²⁵: -4.043 (c = 0.14, CH₃OH).

Preparation of compound (5)

According to the general procedure, alkyne **1a'** (20 mg, 0.06 mmol), *m*-nitrophenylazide (9.8 mg, 0.06 mmol), Cu(OAc)₂ (1.2 mg, 0.006 mmol) and sodium ascorbate (2.4 mg, 0.01 mmol) in ^tBuOH/H₂O (3:3 mL) was stirred at rt for 24 h. The crude mixture was purified by column chromatography (70% ethyl acetate/ petroleum ether) to give the compound **5** (22.3 mg, 72%) as a white solid.

 \mathbf{R}_f : 0.50 (80% ethyl acetate/ petroleum ether).

Mp: 193-195 °C.

¹**H NMR (400 MHz, DMSO):** δ = 1.81 (s, 3H), 2.90-3.02 (m, 3H), 3.03-3.13 (m, 1H), 3.51 (s, 3H), 4.42-4.48(m, 1H), 4.63-4.68 (m, 1H), 7.18-7.26 (m, 5H), 7.89 (t, J = 8.2 Hz, 1H), 8.16-8.18 (m, 1H), 8.30-8.36 (m, 2H), 8.50-8.52 (m, 1H), 8.64-8.68 (m, 2H) ppm.

¹³C NMR (100 MHz, DMSO): δ = 22.5, 28.2, 36.5, 51.8, 51.9, 53.7, 114.5, 121.7, 122.7, 125.9, 126.6, 128.2, 128.3, 19.1, 129.2, 131.7, 137.0, 137.3, 144.5, 148.6, 169.3, 170.8, 171.8 ppm.

I.R. (KBr): 1408.3, 1642.4, 2945.0, 3398.9 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{23}H_{25}N_6O_6 [M+H]^+ 481.1836$, found: 481.1851. [α]_D²⁵: 2.320 (c = 0.17, DMSO).

Preparation of compound (6)

According to the general procedure, alkyne **1a'** (11.2 mg, 0.03 mmol), *p*-nitrophenylazide (5.8 mg, 0.03 mmol), Cu(OAc)₂ (0.7 mg, 0.003 mmol) and sodium ascorbate (1.4 mg, 0.006 mmol) in ^tBuOH/H₂O (3:3 mL) was stirred at rt for 22 h. The crude mixture was purified by column chromatography (60% ethyl acetate/ petroleum ether) to give compound **6** (12.3 mg, 70%) as a white solid.

 \mathbf{R}_f : 0.32 (80% ethyl acetate/ petroleum ether).

Mp: 254-256 °C.

¹H NMR (400 MHz, DMSO): δ = 1.85 (s, 3H), 2.93-3.08 (m, 3H), 3.15-3.20 (m, 1H), 3.57 (s, 3H), 4.51-4.56 (m, 1H), 4.70-4.73 (m, 1H), 7.18-7.27 (m, 5H), 8.10-8.17 (m, 4H), 8.43 (d, J = 8.9 Hz, 2H), 8.58 (s, 1H) ppm.

¹³C NMR (100 MHz, DMSO): δ = 22.4, 28.0, 36.7, 51.7, 53.4, 53.5, 120.1, 121.3, 125.3, 126.4, 128.1, 128.9, 136.8, 141.0, 144.7, 146.5, 169.5, 170.7, 171.6 ppm.

I.R. (KBr): 1408.1, 1652.6, 1742.1, 2950.5, 3393.0 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{23}H_{25}N_6O_6$ [M+H]⁺ 481.1836, found: 481.1856. [α]_D²⁵: -35.444 (c = 0.09, DMSO).

Preparation of compound (7)

According to the general procedure, alkyne **1b** (40 mg, 0.09 mmol), p-chlorophenylazide (14.3 mg, 0.09 mmol), Cu(OAc)₂ (1.8 mg, 0.009 mmol) and sodium ascorbate (3.7 mg, 0.02 mmol) in t BuOH/H₂O (3:3 mL) was stirred at rt for 10 h. The crude mixture was purified by column chromatography (100% ethyl acetate) to give the compound **7** (53.5 mg, 100%) as a white solid.

 \mathbf{R}_f : 0.29 (80% ethyl acetate/ petroleum ether).

Mp: 238-240 °C.

¹**H NMR (400 MHz, CDCl₃):** δ = 2.03 (s, 3H), 2.94-3.15 (m, 3H), 3.32-3.33 (m, 1H), 3.70 (s, 3H), 4.69-4.71 (m, 1H), 4.78-4.79 (m, 1H), 6.78 (d, J = 8.0 Hz, 2H), 6.97 (d, J = 7.6 Hz, 1H), 7.28 (s, 1H), 7.51 (d, J = 8.8 Hz, 2H), 7.56 (d, J = 7.6 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 7.88 (s, 1H) ppm.

¹³C NMR (100 MHz, CDCl₃): δ = 22.8, 27.7, 37.1, 48.7, 48.9, 49.2, 49.4, 49.6, 49.8, 50.0, 52.5, 52.5, 53.4, 92.6, 120.9, 121.7, 130.0, 131.3, 134.7, 135.5, 135.7, 137.7, 144.3, 170.9, 171.3, 171.6 ppm.

I.R. (KBr): 1540.6, 1650.2, 1740.5, 2930.6, 3300.6 cm⁻¹.

HRMS (Q-Tof) m/z: Calcd. $C_{23}H_{24}N_5O_4CII [M+H]^+ 596.0562$, found: 596.0566.

 $[\alpha]_D^{25}$: 35.489 (c = 0.145, CHCl₃).

Preparation of compound (8)

According to the general procedure, alkyne **1b** (20 mg, 0.05 mmol), p-nitrophenylazide (7.6 mg, 0.05 mmol), Cu(OAc)₂ (1 mg, 0.005 mmol) and sodium ascorbate (2 mg, 0.01 mmol) in t BuOH/H₂O (3:3 mL) was stirred at rt for 22 h. The crude mixture was purified by column chromatography (80% ethyl acetate/ petroleum ether) to give the dipeptide **8** (22 mg, 80%) as a white solid.

 \mathbf{R}_f : 0.40 (100% ethyl acetate)

Mp: 277-279 °C

¹**H NMR (400 MHz, DMSO):** δ = 1.75 (s, 3H), 2.78-2.94 (m, 4H), 3.46 (s, 3H), 4.37-4.42 (m, 1H), 4.56-4.62 (m, 1H), 6.96 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 8.2 Hz, 2H), 8.10-8.13 (m, 3H), 8.40-8.45 (m, 3H), 8.60 (s, 1H) ppm.

¹³C NMR (100 MHz, DMSO): δ = 22.4, 28.1, 35.9, 51.8, 51.9, 53.2, 92.5, 120.3, 121.6, 125.6, 131.6, 136.9, 140.9, 144.6, 146.6, 169.2, 170.7, 171.4 ppm.

I.R. (**KBr**): 1437.7, 1652.6, 2824.1, 3429.0 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{23}H_{24}N_6O_6I[M+H]^+607.0802$, found 607.0787.

 $[\alpha]_D^{25}$: 1.733 (c = 0.06, DMSO).

Preparation of compound (9)

According to the general procedure, alkyne **1b** (20 mg, 0.05 mmol), *m*-nitrophenylazide (7.6 mg, 0.05 mmol), Cu(OAc)₂ (1 mg, 0.005 mmol) and sodium ascorbate (2 mg, 0.01 mmol) in ¹BuOH/H₂O (3:3 mL) was stirred at rt for 9 h. The crude mixture was purified by column chromatography (50% ethyl acetate/ petroleum ether) to give the compound **9** (21 mg, 76%) as a white solid.

 \mathbf{R}_f : 0.48 (60% ethyl acetate/ petroleum ether).

Mp: 148-149 °C.

¹**H NMR (400 MHz, DMSO):** δ = 1.81 (s, 3H), 2.89-2.98 (m, 3H), 3.07-3.12 (m, 1H), 3.52 (s, 3H), 4.42-4.48 (m, 1H), 4.62-4.67 (m, 1H), 7.01 (d, J = 8.1 Hz, 2H), 7.58 (d, J = 8.1 Hz, 2H), 7.90 (t, J = 8.2 Hz, 1H), 8.15 (d, J = 8.2 Hz, 1H), 8.31-8.37 (m, 2H), 8.48 (d, J = 7.5 Hz, 1H), 8.67-8.68 (m, 2H) ppm.

¹³C NMR (100 MHz, DMSO): δ = 22.7, 28.3, 36.2, 52.2, 52.3, 53.6, 92.8, 114.8, 122.0, 123.3, 126.2, 131.9, 132.0, 137.1, 137.3, 137.5, 144.7, 148.8, 169.9, 171.1, 171.8 ppm.

I.R. (**KBr**): 1437.6, 1660.1, 3422.1 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{23}H_{24}N_6O_6I [M+H]^+ 607.0802$, found 607.0789. [α]_D²⁵: 2.672 (c = 0.11, DMSO).

Preparation of compound (11)

According to the general procedure, alkyne **10** (30 mg, 0.09 mmol), *p*-methoxyphenyl azide (27.9 mg, 0.19 mmol), Cu(OAc)₂ (3.7 mg, 0.02 mmol) and sodium ascorbate (7.4 mg, 0.04 mmol) in ¹BuOH/H₂O (3:3 mL) was stirred at rt for 24 h. The crude mixture was purified by column chromatography (100% ethyl acetate) to give the compound **11** (57 mg, 99%) as a white solid.

 \mathbf{R}_f : 0.16 (100% ethyl acetate).

Mp: 210-213 °C.

¹H NMR (400 MHz, CDCl₃): δ = 0.88-0.92 (m, 6H), 1.57-1.64 (m, 2H), 2.07 (bs, 1H), 2.08 (s, 3H), 3.40-3.68 (m, 4H), 3.69 (s, 3H), 3.87 (s, 6H), 4.41-4.43 (m, 1H), 7.00-7.02 (m, 4H), 7.35 (bs, 1H), 7.64-7.70 (m, 4H), 8.04 (s, 1H), 8.08 (s, 1H), 8.19 (d, J = 6.8 Hz, 1H) ppm.

¹³C NMR (100 MHz, CDCl₃): δ = 20.8, 21.9, 22.9, 24.6, 25.1, 30.6, 31.1, 40.9, 51.8, 52.3, 55.8, 64.0, 114.8, 114.9, 122.1, 122.1, 122.5, 122.7, 130.6, 130.7, 142.9, 142.4, 159.9, 159.9, 172.3, 172.4, 173.6 ppm.

I.R. (KBr): 1685.1, 1736.3, 2928.7, 3054.7 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{31}H_{39}N_8O_6 [M+H]^+ 619.2993$, found: 619.2994. $[\alpha]_D^{25}$: - 7.494 (c = 0.17, CHCl₃).

Preparation of compound (12)

According to the general procedure, alkyne **10** (40 mg, 0.12 mmol), *p*-chlorophenyl azide (38.5 mg, 0.25 mmol), Cu(OAc)₂ (3.7 mg, 0.02 mmol) and sodium ascorbate (7.4 mg, 0.04 mmol) in ^tBuOH/H₂O (3:3 mL) was stirred at rt for 24 h. The crude mixture was purified by

column chromatography (80% ethyl acetate/ petroleum ether) to give the compound **12** (72 mg, 92%) as a white solid.

 \mathbf{R}_f : 0.45 (100% ethyl acetate).

Mp: 243-245 °C.

¹**H NMR (400 MHz, CDCl₃):** δ = 0.85-0.94 (m, 6H), 1.25 (bs, 3H), 2.08 (s, 3H), 3.36-3.42 (m, 2H), 3.53 (d, J = 15.2 Hz, 1H), 3.71 (s, 3H), 3.84 (d, J = 15.2 Hz, 1H), 4.38-4.39 (m, 1H), 7.29 (s, 1H), 7.48-7.52 (m, 4H), 7.72 (d, J = 8.8 Hz, 2H), 7.78 (d, J = 8.8 Hz, 2H), 8.14 (s, 1H), 8.25 (s, 1H), 8.30 (d, J = 6.8 Hz, 1H) ppm.

¹³C NMR (100 MHz, CDCl₃): $\delta = 21.9$, 22.9, 24.6, 25.1, 30.5, 31.1, 40.8, 51.8, 52.4, 63.9, 121.6, 121.7, 122.5, 122.7, 130.0, 130.1, 134.5, 134.7, 135.6, 135.8, 143.2, 143.9, 172.3, 172.4, 173.8 ppm.

I.R. (**KBr**): 1409.5, 1654.3, 2951.5, 3389.3 cm⁻¹.

HRMS (Q-Tof) m/z: Calcd. C₂₉H₃₃N₈O₄Cl₂ [M+H]⁺ 627.200, found: 627.201. [α] $_{D}^{25}$: - 3.05(c = 0.67, CHCl₃).

Preparation of compound (13)

According to the general procedure, alkyne **10** (20 mg, 0.06 mmol), *o*-nitronitrophenyl azide (19.7 mg, 0.12 mmol), Cu(OAc)₂ (1.8 mg, 0.01 mmol) and sodium ascorbate (3.6 mg, 0.02 mmol) in ^tBuOH/H₂O (3:3 mL) was stirred at rt for 24 h. The crude mixture was purified by column chromatography (5% methanol/chloroform) to give the compound **13** (30.2 mg, 74%) as a white solid.

 \mathbf{R}_f : 0.64 (10% methanol/ chloroform).

Mp: 165-167 °C.

¹**H NMR (400 MHz, CD₃OD):** δ = 0.89 (d, J = 6.2 Hz, 3H), 0.93 (d, J = 6.2 Hz, 3H), 1.57-1.68 (m, 1H), 1.71-1.94 (m, 2H), 2.02 (s, 3H), 3.48-3.60 (m, 3H), 3.67 (s, 3H), 3.69-3.72 (m, 1H), 4.42-4.46 (m, 1H), 7.78-7.89 (m, 4H), 7.90-7.92 (m, 2H), 8.12-8.15 (m, 2H), 8.26 (s, 1H), 8.32 (s, 1H) ppm.

¹³C NMR (100 MHz, CD₃OD): $\delta = 21.8, 23.4, 25.8, 30.8, 31.9, 41.3, 52.7, 52.8, 63.8, 126.8, 127.2, 128.9, 131.2, 131.3, 132.4, 135.2, 135.3, 143.8, 144.5, 146.1, 173.4, 173.9, 175.3 ppm.$

I.R. (**KBr**): 1537.7, 1667.1, 1743.1, 2955.5, 3365.6 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{29}H_{33}N_{10}O_8 [M+H]^+ 649.2483$, found: 649.2489. [α]_D²⁵: - 29.194 (c = 0.37, CHCl₃).

Preparation of compound (14)

According to the general procedure, alkyne **10** (30 mg, 0.09 mmol), p-nitrophenyl azide (31.2 mg, 0.19 mmol), Cu(OAc)₂ (3.7 mg, 0.02 mmol) and sodium ascorbate (7.4 mg, 0.04 mmol) in t BuOH/H₂O (3:3 mL) was stirred at rt for 22 h. The crude mixture was purified by column chromatography (5% methanol/ chloroform) to give the compound **14** (40 mg, 66%) as a white solid.

 \mathbf{R}_f : 0.74 (10% methanol/ chloroform).

Mp: 172-174 °C.

¹H NMR (400 MHz, DMSO+CD₃OD): δ = 0.72 (d, J = 6.4 Hz, 3H), 0.81 (d, J = 6.4 Hz, 3H), 1.37-1.65 (m, 3H), 1.89 (s, 3H), 3.40-3.52 (m, 4H), 3.58 (s, 3H), 4.19-4.22 (m, 2H), 8.15-8.21 (m, 4H), 8.31 (d, J = 7.1 Hz, 1H), 8.43-8.45 (m, 4H), 8.62 (s, 1H), 88.69, (s, 1H) ppm.

¹³C NMR (100 MHz, DMSO+CD₃OD): δ =22.3, 24.2, 24.7, 25.2, 30.3, 31.7, 34.7, 52.3, 53.3, 63.1, 111.1, 120.3, 121.3, 123.7, 126.3, 127.0, 128.9, 142.2, 142.3, 144.8, 145.2, 147.9, 148.0, 171.5, 172.8, 174.9 ppm.

I.R. (KBr): 1663.1, 1736.3, 2917.7, 3422.7 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{29}H_{33}N_{10}O_8 [M+H]^+ 649.2483$, found: 649.2476. [α]_D²⁵: 9.422 (c = 0.22, DMSO).

Preparation of compound (15)

According to the general procedure, alkyne **10** (20 mg, 0.06 mmol), 2-methoxy-4-nitrophenyl azide (23.7 mg, 0.12 mmol), $Cu(OAc)_2$ (1.8 mg, 0.01mmol) and sodium ascorbate (3.6 mg, 0.02 mmol) in ${}^{t}BuOH/H_2O$ (3:3 mL) was stirred at rt for 24 h. The crude mixture was purified by column chromatography (70% ethyl acetate/ petroleum ether) to give the compound **15** (32.1 mg, 85%) as a white solid.

 \mathbf{R}_{f} : 0.36 (60% ethyl acetate/ petroleum ether).

Mp: 205-207 °C.

¹**H NMR (400 MHz, CDCl₃):** δ = 0.86-0.91 (m, 6H), 1.61-1.74 (m, 3H), 2.09 (s, 3H), 3.51-3.71 (m, 4H), 3.64 (s, 3H), 4.07 (s, 6H), 4.44-4.48 (m, 1H), 7.29 (bs, 1H), 7.79 (s, 2H), 8.01-8.08 (m, 3H), 8.13 (d, J = 8.7 Hz, 2H), 8.32 (d, J = 4.7 Hz, 2H) ppm.

¹³C NMR (100 MHz, CDCl₃): δ = 21.9, 22.9, 24.6, 25.1, 30.8, 31.3, 41.1, 51.5, 52.3, 56.9, 57.0, 64.1, 107.9, 108.1, 116.8, 116.9, 125.2, 125.3, 126.2, 126.3, 131.1, 131.2, 142.7, 143.1, 148.2, 150.8, 151.9, 171.9, 172.2, 173.3 ppm.

I.R. (**KBr**): 1457.7, 1525.1, 1650.6, 2925.1, 3399.1 cm⁻¹. **HRMS** (**Q-Tof**) m/z: Calcd. $C_{31}H_{37}N_{10}O_{10}$ [M+H]⁺ 709.269, found: 709.272. [α]_D²⁵: - 5.22 (c = 0.09, CHCl₃).

Preparation of compound (16)

To a solution of dipeptide **10** (267 mg, 0.83 mmol) in methanol (10 mL) was added 2N NaOH (0.31 mL) and the reaction mixture was stirred at rt for 24 h. Then the reaction mixture was concentrated, diluted with water (6 mL), then acidified with 1N HCl and extracted with ethyl acetate. Evaporation of the solvent gave **16** (250 mg, 98%) as a white solid, which was directly used in the subsequent reaction.

 \mathbf{R}_f : 0.32 (20% methanol/ chloroform).

Mp: 213-215 °C

¹**H NMR (400 MHz, CD₃OD):** δ = 0.89-0.94 (m, 6H), 1.57-1.76 (m, 3H), 1.99 (s, 3H), 2.36-2.40 (m, 2H), 2.86-3.06 (m, 4H), 4.47-4.90 (m, 1H) ppm.

¹³C NMR (100 MHz, CD₃OD): δ = 22.0, 22.8, 22.9, 23.6, 25.5, 25.7, 42.3, 52.3, 61.9, 73.3, 73.3, 79.4, 79.5 ppm.

I.R. (**KBr**): 1665.3, 2104.1, 3356.7 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{16}H_{23}N_2O_4$ [M+H]⁺ 307.1658, found: 307.1652. [α]_D²⁵: - 26.91 (c = 0.13, CH₃OH).

Preparation of compound (17)

To a solution of acid **16** (130 mg, 0.42 mmol) and HOBt (114.6 mg, 0.84 mmol) in dry THF (10 mL) was added DCC (103.6 mg, 0.50 mmol) at 0 $^{\circ}$ C. Then, H-Leu-OMe.HCl (70.3 mg, 0.50 mmol) and NMM (33.9 mg, 0.33 mmol, reaction mixture should have around pH 9) in THF (10 mL) solution was added. The reaction mixture was stirred at rt for 24 h. The solvent was evaporated and the residue was diluted with water. The aqueous layer was extracted with ethyl acetate (3 × 10 mL). The combined organic layer was washed with water, brine and dried over Na₂SO₄. Evaporation of the solvent gave the crude product, which was purified by column chromatography (1% methanol/ chloroform) to give the tripeptide **17** (120.5 mg, 70%) as a white solid.

 \mathbf{R}_f : 0.38 (5% methanol/ chloroform).

Mp: 104-106 °C.

¹**H NMR (400 MHz, CDCl₃):** δ = 0.92-0.95 (m, 6H), 1.42 (d, J = 7.2 Hz, 3H), 1.52-1.61(m, 1H), 1.69-1.78 (m, 2H), 2.09 (s, 3H), 2.11 (t, J = 2.6 Hz, 1H), 2.16 (t, J = 2.6 Hz, 1H), 2.94-3.22 (m, 4H), 3.73 (s, 3H), 4.47-4.55 (m, 2H), 6.45 (s, 1H), 6.75 (d, J = 8.1 Hz, 1H), 6.99 (d, J = 7.1 Hz, 1H) ppm.

¹³C NMR (100 MHz, CDCl₃): δ = 17.9, 21.6, 23.3, 23.9, 24.8, 24.9, 25.6, 40.6, 48.3, 52.4, 52.5, 60.9, 72.7, 73.2, 78.7, 79.1, 170.3, 171.3, 171.5, 173.2 ppm.

I.R. (**KBr**): 1542.0, 1650.9, 1743.5, 2279.1, 2950.0, 3285.3 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. for $C_{20}H_{30}N_3O_5$ [M+H]⁺ 392.2185, found at 392.2167. [α]_D²⁵: - 15.541 (c = 0.76, CHCl₃).

Preparation of compound (18)

According to the general procedure, alkyne **17** (20 mg, 0.05 mmol), 2-methoxy-4-nitrophenyl azide (18.6 mg, 0.10 mmol), Cu(OAc)₂ (1.8 mg, 0.01mmol) and sodium ascorbate (3.6 mg, 0.02 mmol) in ^tBuOH/H₂O (3:3 mL) was stirred at rt for 10 h. The crude mixture was purified by column chromatography (1% methanol/ chloroform) to give the compound **18** (32 mg, 84%) as a white solid.

 \mathbf{R}_f : 0.22 (5% methanol/ chloroform).

Mp: 135-137 °C.

¹H NMR (400 MHz, CD₃OD): δ = 0.86 (d, J = 6.3 Hz, 3H), 0.91 (d, J = 6.4 Hz, 3H), 1.39 (d, J = 7.4 Hz, 3H), 1.62-1.66 (m, 3H), 2.08 (s, 3H), 3.41-3.64 (m, 4H), 3.69 (s, 3H), 4.12 (s, 3H), 4.13 (s, 3H), 4.27-4.32 (m, 1H), 4.41-4.47 (m, 1H), 8.07-8.08 (m, 4H), 8.15 (bs, 2H), 8.45 (s, 1H), 8.51 (s, 1H) ppm.

¹³C NMR (100 MHz, CD₃OD): δ = 15.6, 20.3, 22.1, 22.2, 24.1, 28.9, 29.3, 30.1, 39.9, 51.3, 51.9, 56.2, 62.5, 107.8, 107.9, 115.9, 116.0, 125.1, 125.2, 126.1, 130.7, 130.8, 141.9, 142.3, 148.5, 151.4, 151.5, 172.3, 173.2, 173.5 ppm.

I.R. (**KBr**): 1531.2, 1651.8, 2924.3, 3389.5 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{34}H_{42}N_{11}O_{11}$ [M+H]⁺ 780.3065, found: 780.3046. [α]_D²⁵: - 22.05 (c = 0.08, CHCl₃).

Preparation of compound (19)

According to the general procedure, alkyne **17** (20 mg, 0.05 mmol), p-chloronitrophenyl azide (15.3 mg, 0.10 mmol), Cu(OAc)₂ (1.8 mg, 0.01 mmol) and sodium ascorbate (3.6 mg, 0.02

mmol) in ^tBuOH/H₂O (3:3 mL) was stirred at rt for 18 h. The crude mixture was purified by column chromatography (1% methanol/ chloroform) to give the compound **19** (28.8 mg, 84%) as a white solid.

 \mathbf{R}_f : 0.22 (80% ethyl acetate/ petroleum ether).

Mp: 172-174 °C.

¹H NMR (400 MHz, CDCl₃): δ = 0.78-0.89 (m, 6H), 1.36 (d, J = 7.2 Hz, 3H),1.37-1.72 (m, 3H), 2.08 (s, 3H), 3.49-3.79 (m, 4H), 3.71 (s, 3H), 4.30-4.32 (m, 1H), 4.33-4.48 (m, 1H), 7.29 (d, J = 7.1 Hz, 1H), 7.33 (s, 1H), 7.48-7.52 (m, 4H), 7.69-7.71 (m, 5H), 8.10 (s, 1H), 8.14 (s, 1H) ppm.

¹³C NMR (100 MHz, CDCl₃): δ = 17.7, 21.6, 23.1, 24.6, 24.9, 30.8, 30.9, 40.6, 48.5, 52.5, 52.9, 63.6, 121.5, 121.6, 122.2, 122.3, 130.1, 130.2, 134.6, 134.8, 135.4, 135.6, 143.4, 143.6, 172.0, 172.1, 173.3 ppm.

I.R. (**KBr**): 1501.8, 1647.2, 1662.5, 1739.3, 2945.0 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{32}H_{38}N_9O_5Cl_2 [M+H]^+ 698.2373$, found: 698.2380. [α]_D²⁵: 3.814 (c = 0.14, CH₃OH).

Preparation of compound (20)

According to the general procedure, alkyne **17** (20 mg, 0.05 mmol), *p*-methoxyphenylazide (14.6 mg, 0.10 mmol), Cu(OAc)₂ (1.8 mg, 0.01mmol) and sodium ascorbate (3.6 mg, 0.02 mmol) in ^tBuOH/H₂O (3:3 mL) was stirred at rt for 20 h. The crude mixture was purified by column chromatography (5% methanol/ chloroform) to give the compound **20** (29.5 mg, 85%) as a white solid.

 \mathbf{R}_f : 0.45 (10% methanol/ chloroform).

Mp: 130-132 °C.

¹**H NMR (400 MHz, CDCl₃):** δ = 0.78-0.83 (m, 6H), 1.37 (d, J= 7.2 *Hz*, 3H), 1.49-1.58 (m, 2H), 1.71-1.79 (m, 1H), 2.08 (s, 3H), 3.51-3.66 (m, 2H), 3.71-3.74 (m, 2H), 3.74 (s, 3H), 3.87 (s, 6H), 4.34-4.46 (m, 1H), 4.48-4.53 (m, 1H), 7.02 (d, *J* = 9.0 Hz, 4H), 7.36-7.39 (m, 2H), 7.51 (d, *J*= 7.4 Hz, 1H), 7.60-7.68(m, 4H), 7.92(s, 1H), 7.95 (s, 1H) ppm.

¹³C NMR (100 MHz, CDCl₃): δ = 17.9, 21.6, 22.9, 23.2, 24.7, 24.9, 30.7, 31.2, 40.5, 48.4, 52.5, 52.8, 55.8, 63.8, 114.9, 115.0, 122.0, 122.2, 122.4, 130.5, 130.7, 143.2, 159.9, 160.1, 171.9, 171.9, 172.2, 173.3 ppm.

I.R. (KBr): 1519.1, 1657.1, 1743.4, 2836.6, 2929.4 cm⁻¹.

HRMS (**Q-Tof**) m/z: Calcd. $C_{34}H_{44}N_9O_7$ [M+H]⁺ 690.3364, found: 690.3385. [α]_D²⁵: - 10.66 (c = 0.14, CHCl₃).

Table S1: List of various triazole based peptides synthesized

Alkyne precussor	Azide	Mono-triazole based peptide
HN COOMe H 1a	N ₃	N-N COOMe HN H O 2 ACHN H 97%
HN COOMe Achn H	N ₃ NO ₂	N-N COOMe HN H AcHN H 82%
HN COOMe H Achn H 1a'	N ₃ NO ₂	N-N COOMe HN H AcHN H 88%

contd.....

Alkyne precussor	Azide	Mono-triazole based peptide
HN COOMe H 1a'	N ₃ NO ₂	NO ₂ N-N COOMe HN H 5 72%
HN COOMe Achn H O 1a'	N ₃	O ₂ N COOMe H 6 70%
HN COOMe H 1b	N ₃	N-N COOMe HN H 7 O 100%
HN = COOMe H O 1b	N ₃	O ₂ N N-N COOMe HN H 8 80%
HN COOMe H 1b	N ₃	NO ₂ N-N COOMe HN H 9 76% Achn Achn H

contd....

Alkye precussor	Azide	Di-triazole based peptide
AcHN H COOMe	N ₃ OCH ₃	MeOOC N N N N N OCH ₃
AcHN H COOMe	2 3 - C	MeOOC N NHAC 92%
AcHN H COOMe	N ₃ NO ₂	MeOOC N N N N N N N N N N N N N N N N N N
AcHN H COOMe	N ₃	MeOOC N N N N N N N NO2
AcHN H COOMe	N ₃ OCH ₃ NO ₂	O 15 MeOOC H H H N N N N N N N N N N N N N N N N

• • • •

Alkye Precussor	Azide	Di-triazole Based Tripeptide Yield(%)
AcHN H H COOCH ₃	N ₃ OMe NO ₂	MeOOC N N N N N N N N N N N N N N N N N N
AcHN H H O N COOCH ₃	N 3 CI	MeOOC H O 19 NHAC 84% NN N N N CI
AcHN H H COOCH ₃	N ₃ OCH ₃	MeOOC H O 20 NHAC 85% NN N N N OCH3







Figure S1. Screening of different inhibitors against MST1 kinase. A) with compound **7** B) with compound **8** C) with compound **9** D) with compound **12**


 $^1\mbox{H}$ NMR (400 MHz, CDCl3) and $^{13}\mbox{C}$ NMR (100 MHz, CDCl3) and HRMS of compound 2






¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃+CD₃OD) and HRMS of compound 3










 $^1H\ NMR\ (400\ MHz,\ CD_3OD)\ \ and\ \ ^{13}C\ NMR\ (100\ MHz,\ CD_3OD)$ and HRMS of compound


4







¹H NMR (400 MHz, DMSO) and ¹³C NMR (100 MHz, DMSO) and HRMS of compound







 $^1\mbox{H NMR}$ (400 MHz, DMSO) and $^{13}\mbox{C NMR}$ (100 MHz, DMSO) and HRMS of compound







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) and HRMS of compound










 $^1\text{H NMR}$ (400 MHz, DMSO) and $^{13}\text{C NMR}$ (100 MHz, DMSO) and HRMS of compound 8







H NMR (400 MHz, DMSO) and ¹³C NMR (100 MHz, DMSO) and HRMS of compound







 $^1\text{H NMR}$ (400 MHz, CDCl₃) and $^{13}\text{C NMR}$ (100 MHz, CDCl₃) and HRMS of compound 11







H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) and HRMS of compound







 1H NMR (400 MHz, CD₃OD) and ^{13}C NMR (100 MHz, CD₃OD) and HRMS of compound 12







H NMR (400 MHz, DMSO) and ¹³C NMR (100 MHz, DMSO) and HRMS of compound







 1H NMR (400 MHz, CDCl₃) and ^{13}C NMR (100 MHz, CDCl₃) and HRMS of compound 15







H NMR (400 MHz, CD₃OD) and ¹³C NMR (100 MHz, CD₃OD) and HRMS of compound






 1H NMR (400 MHz, CDCl₃) and ^{13}C NMR (100 MHz, CDCl₃) and HRMS of compound 17







¹H NMR (400 MHz, CD₃OD) and ¹³C NMR (100 MHz, CD₃OD) and HRMS of compound


18





 ^1H NMR (400 MHz, CDCl₃) and ^{13}C NMR (100 MHz, CDCl₃) and HRMS of compound 19





$^{1}\text{H NMR}$ (400 MHz, CDCl₃) and $^{13}\text{C NMR}$ (100 MHz, CDCl₃) and HRMS of compound 20

